CiteScore measures average citations received per document published in the serial.
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Indexed in the following public directories
Overview | |
Publisher | ELSEVIER |
Language | English |
Frequency | Continuous publication |
Article Processing Charges | USD 2050 |
Publication Time | 11 |
Editorial Review Process | Anonymous peer review |
General Details | |
Language | English |
Society/Institute/Sponsor | European Atherosclerosis Society |
Frequency | Continuous publication |
Publisher URL | Visit website |
Website URL | Visit website |
Publication Details | |
Plagiarism | Visit website |
Waiver Policy | Visit website |
Publication Time | 11 |
Article Processing Charges | USD 2050 |
Editorial Review Detail | |
Editorial Team | Visit website |
Review Process | Anonymous peer review |
Review Url | Visit website |
Information for authors | |
Author instructions | Visit website |
Copyright Details | Visit website |
License type | CC BY, CC BY-NC-ND |
OA statement | Visit website |
Upload your Manuscript to get
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my Paper189 articles received 178 citations see all
Atherosclerosis Plus published with a Continuous publication frequency.
For Atherosclerosis Plus,eISSN is 2667-0895 and pISSN is2667-0909.
Citescore for Atherosclerosis Plus is 2.
SNIP score for Atherosclerosis Plus is 0.42.
ELSEVIER is the publisher of Atherosclerosis Plus.